In this video


AstraZeneca U.S. president explains trial data, plans for filing for U.S. approval

The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization. Ruud Dobber, president of AstraZeneca U.S., joined CNBC's Meg Tirrell and the CNBC's "Squawk Box" crew on Monday to discuss the results.
Mon, Mar 22 20217:13 AM EDT